PHARMACODYNAMIC INTERACTION BETWEEN TAK-442, AN ORAL DIRECT FACTOR XA INHIBITOR, AND PRASUGREL IN HEALTHY SUBJECTS

被引：0
|
作者：
Wood, Nolan [1 ]
Stringer, Fran [1 ]
Wu, Ruishan [1 ]
Kawamura, Masaki [1 ]
Spaeder, Jeff [1 ]
机构：
[1] Takeda Global Res & Dev Inc, Deerfield, IL USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2011年 / 57卷 / 14期
关键词：
D O I：
10.1016/S0735-1097(11)61504-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E1504 / E1504
页数：1
相关论文
共 50 条
  • [21] Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor in healthy subjects
    Mueck, W.
    Becka, M.
    Kubitza, D.
    Voith, B.
    Zuehlsdorf, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (06) : 335 - 344
  • [22] Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects
    Kadokura, Takeshi
    Taniuchi, Yuta
    Inoue, Hiroshi
    Saito, Masako
    Iwahana, Mioko
    Yamada, Shunsuke
    Urae, Akinori
    Nakamura, Mashio
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (03) : 200 - 206
  • [23] EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Uprett, Vijay V.
    Song, Yan
    Wang, Jessie
    Farmer, Mathew
    Pursley, Janica M.
    Li, Tong
    Frost, Charles E.
    LaCreta, Frank P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1117 - 1117
  • [24] TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1
    Shinozawa, Emiko
    Nakayama, Masaharu
    Imura, Yoshimi
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [25] Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects
    Kubitza, D.
    Becka, M.
    Roth, A.
    Mueck, W.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2012, 40 (05) : 1688 - 1707
  • [26] Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
    Fujimoto, Takuya
    Imaeda, Yasuhiro
    Konishi, Noriko
    Hiroe, Katsuhiko
    Kawamura, Masaki
    Textor, Garret P.
    Aertgeerts, Kathleen
    Kubo, Keiji
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (09) : 3517 - 3531
  • [27] Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis (vol 56, pg 156, 2010)
    Kawamura, M.
    Konishi, N.
    Hiroe, K.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (04) : 439 - 439
  • [28] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN HEALTHY SUBJECTS.
    Xuan, D.
    Boyd, R.
    DiCarlo, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S54 - S55
  • [29] EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Upreti, Vijay V.
    Wang, Jessie
    Barrett, Yuchen
    Boyd, Rebecca
    Bui, Anh
    Li, Tong
    LaCreta, Frank P.
    Frost, Charles E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1060 - 1060
  • [30] Co-administration of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and clopidogrel in healthy subjects
    Kubitza, D.
    Becka, M.
    Mueck, W.
    Zuehlsdorf, M.
    EUROPEAN HEART JOURNAL, 2007, 28 : 189 - 189
12345